TY - JOUR
T1 - Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation
AU - Nelson, Robert P.
AU - Khawaja, Muhammad Rizwan
AU - Perkins, Susan M.
AU - Elmore, Lindsey
AU - Mumaw, Christen L.
AU - Orschell, Christie
AU - Paczesny, Sophie
N1 - Publisher Copyright:
© 2014 American Society for Blood and Marrow Transplantation.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days+7,+14,+21, and+30. At a median follow-up of 358days, 17 patients had experienced aGVHD with a median time to onset at day+36. Risk of aGVHD wasassociated with elevated plasma ST2 concentrations at day+7 (c-statistic=72, P=03), day+14 (c-statistic=74, P=02), and day+21 (c-statistic=75, P=02); elevated plasma REG3α concentrations at day+14 (c-statistic=73, P=03), day+21 (c-statistic=76, P=01), and day+30 (c-statistic=73, P=03); and elevated elafin at day+14 (c-statistic=71, P=04). Plasma concentrations of TNFR1 and sIL2Rα were not associated with aGVHD risk at any of the time points studied. Thisstudy identified ST2, REG3α, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort.
AB - Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days+7,+14,+21, and+30. At a median follow-up of 358days, 17 patients had experienced aGVHD with a median time to onset at day+36. Risk of aGVHD wasassociated with elevated plasma ST2 concentrations at day+7 (c-statistic=72, P=03), day+14 (c-statistic=74, P=02), and day+21 (c-statistic=75, P=02); elevated plasma REG3α concentrations at day+14 (c-statistic=73, P=03), day+21 (c-statistic=76, P=01), and day+30 (c-statistic=73, P=03); and elevated elafin at day+14 (c-statistic=71, P=04). Plasma concentrations of TNFR1 and sIL2Rα were not associated with aGVHD risk at any of the time points studied. Thisstudy identified ST2, REG3α, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort.
UR - http://www.scopus.com/inward/record.url?scp=84908021017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908021017&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.06.039
DO - 10.1016/j.bbmt.2014.06.039
M3 - Article
C2 - 25017764
AN - SCOPUS:84908021017
SN - 1083-8791
VL - 20
SP - 1861
EP - 1864
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -